Person: GEÇER, MELİN
Loading...
Status
Organizational Units
8 results
Search Results
Now showing 1 - 8 of 8
Publication Metadata only DERİ EKİ TÜMÖRLERİ(Akademisyen Yayınevi Kitabevi, 2022-12-01) Geçer M.; GEÇER, MELİNPublication Metadata only Stem cell markers: A guide to neoadjuvant therapy in breast carcinomas(2022-06-01T00:00:00Z) Gücin, Zühal; Büyükpınarbaşılı, Nur; Geçer, Melin; Ersoy, Yeliz Emine; Türk, Hacı Mehmet; Yıldız, Şeyma; Aksoy, Direnç Özlem; GÜCİN, ZÜHAL; GEÇER, MELİN; ERSOY, YELIZ EMINE; TÜRK, HACI MEHMET; YILDIZ, ŞEYMABACKGROUND: In recent years, stem cells have been defined as the main cell population responsible for resistance to anticancer therapies. AIM: This study aims to investigate potential associations between the stem cell population and the degree of tumor regression in breast carcinomas treated with neoadjuvant therapy. SETTINGS AND DESIGN: The study included 92 patients with breast carcinoma who received neoadjuvant therapy. Tumor regression was defined based on Miller and Payne grading system. Patients with grade 1 or 2 regression on a 5‑point scale were included in group 1 (n = 37), grade 3 regression in group 2 (n = 32), and grade 4 or 5 regression in group 3 (n = 23). MATERIALS AND METHODS: Immunohistochemical staining was performed on paraffin block sections of every case using CD44, CD24, CD29, CD133, ID4, and ALDH1 antibodies to detect stem cells. STATISTICAL ANALYSIS USED: IBM Statistical Package for the Social Sciences (SPSS), version 23.0 (IBM Corp., Armonk, NY, USA) software was used for statistical analyses, and a P value less than 0.05 was considered statistically significant. RESULTS: Histologically high‑grade tumors are more common in the near‑complete/complete response group (P = 0.004). HER2‑positive tumors were more common in the complete/ near‑complete response group (P = 0.054). Tumor cells positive for stem cell markers CD44 and CD24 were more common in the poor response group (P = 0.027 and P = 0.001, respectively). CD29 expression was reduced in the posttreatment residual tumor tissue in the near‑complete/complete response group. CONCLUSION: High CD44 and CD24 expression may be a predictor of poor response/nonresponse to neoadjuvant therapy in breast carcinomas. KEY WORDS: Breast Cancers, neoadjuvant treatment, stem cell markers, stem cells, tumor regression gradePublication Metadata only Nodule on scalp: As a metastatic gastric cancer(2020-11-01) Yeniocak A.; ÇAMLI M. F.; GEÇER M.; YILDIZ K.; YENİOCAK, ALİ; ÇAMLI, MEHMET FATİH; GEÇER, MELİN; YILDIZ, KEMALETTİNPublication Open Access A Primary Adenosquamous Carcinoma of the Stomach: Report of Two Cases(2017-07-01) Gecer, MELİN; Unver, NURCAN; HASBAHCECI, Mustafa; Gucin, ZÜHAL; Tosuner, ZEYNEP; Akcakaya, ADEM; Arici, Sema; GEÇER, MELİN; ÜNVER, NURCAN; GÜCİN, ZÜHAL; TOSUNER, ZEYNEP; ÇOBAN, EZGİ; AKÇAKAYA, ADEM; ARICI, DILEK SEMAPrimary gastric adenosquamous carcinomas are extremely rare tumors. A gradual transition between the malignant glandular and squamous components of the tumor is seen on performing a histopathological evaluation. These tumors are known to have poorer clinical outcomes than conventional adenocarcinomas. We aimed to present two cases of primary adenosquamous carcinomas that were diagnosed at the later stage in our institute.Publication Metadata only Digital Papiller Adenokarsinom(Akademisyen Yayınevi Kitabevi, 2022-10-01) Geçer M.; GEÇER, MELİNPublication Metadata only EFFECT OF STAT3 STATUS ON RAS & RAF MUTATION IN PATIENTS WITH METASTATIC COLON CARCINOMA(2023-10-29) Geçer M.; Turna S.; Gül B.; Gücin Z.; GEÇER, MELİN; TURNA, SEVAL; GÜL, BURCU; GÜCİN, ZÜHALPublication Metadata only Burnun Soliter Nörofibromu: Olgu sunumu(2021-11-14) Sönmez Ergün S.; Kirazoğlu A.; Çamlı M. F.; Koç C.; Geçer M.; ERGÜN, SELMA; ÇAMLI, MEHMET FATİH; KOÇ, CAN; GEÇER, MELİNPublication Metadata only Silindroma sonrası gelişen Trikoblastik Karsinom(2023-11-01) Çamlı M. F.; Demir F. O.; Geçer M.; Tekçe E.; Yıldız K.; ÇAMLI, MEHMET FATİH; DEMİR, FATİH OSMAN; GEÇER, MELİN; TEKÇE, ERTUĞRUL; YILDIZ, KEMALETTİN